Bortezomib is a proteasome inhibitor with pleotropic antitumor effects, including putative activity targeting NF-κB. Elevated levels of NF-κB DNA binding have been documented in HL and NF-κB activity is thought to mediate resistance to standard therapeutic approaches. Despite this rationale, and significant activity in non-Hodgkin lymphoma (NHL), the experience to date with bortezomib in HL has been disappointing. Studies in solid tumor lines have suggested that bortezomib markedly enhances cytotoxicity of gemcitabine, a nucleoside analog with significant activity against HL. Thus, we combined bortezomib with gemcitabine in a prospective trial for patients (pts) with relapsed HL. Eligible pts had confirmed relapsed classical HL and normal organ function. Based upon phase I data in solid tumors (
Disclosure:Research Funding: Lilly and Millenium. Membership Information: Lilly DSMB. Off Label Use: Gemcitabine and bortezomib for Hodgkin lymphoma.